Bioinformatics-driven discovery of novel EGFR kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation

Bioinformatics-driven discovery of novel EGFR kinase inhibitors as anti-cancer therapeutics: In silico screening and in vitro evaluation

Bibliographic Details
Main Authors:	Awwad A. Radwan, Fars Alanazi, Abdullah Al-Dhfyan
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2024-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11020408/?tool=EBI

Similar Items

Design and synthesis of multi-functional small-molecule based inhibitors of amyloid-β aggregation: Molecular modeling and in vitro evaluation
by: Awwad A. Radwan, et al.
Published: (2023-01-01)

Design and synthesis of multi-functional small-molecule based inhibitors of amyloid-β aggregation: Molecular modeling and in vitro evaluation.
by: Awwad A Radwan, et al.
Published: (2023-01-01)

Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study
by: Duangjai Todsaporn, et al.
Published: (2023-03-01)

Identification of Vinyl Sulfone Derivatives as EGFR Tyrosine Kinase Inhibitor: In Vitro and In Silico Studies
by: Thitinan Aiebchun, et al.
Published: (2021-04-01)

Combined Modeling Study of the Binding Characteristics of Natural Compounds, Derived from Psoralea Fruits, to β-Amyloid Peptide Monomer
by: Awwad Radwan, et al.
Published: (2022-03-01)

Editorial: Discovery of EGFR tyrosine kinase inhibitors for cancer treatment
by: Panupong Mahalapbutr, et al.
Published: (2024-02-01)

In Silico and In Vitro Screening of 50 Curcumin Compounds as EGFR and NF-κB Inhibitors
by: Mohamed E. M. Saeed, et al.
Published: (2022-04-01)

In Silico and In Vitro Study of Janus Kinases Inhibitors from Naphthoquinones
by: Kamonpan Sanachai, et al.
Published: (2023-01-01)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
by: Ming-Hung Huang, PhD, et al.
Published: (2022-11-01)

In silico discovery of potential uridine-cytidine kinase 2 inhibitors form the rhizome of Alpina mutica
by: Malami, Ibrahim, et al.
Published: (2016)

In Vitro and In Silico Evaluation of Anticancer Activity of New Indole-Based 1,3,4-Oxadiazoles as EGFR and COX-2 Inhibitors
by: Belgin Sever, et al.
Published: (2020-11-01)

In silico and in vitro evaluation of novel carbothioamide-based and heterocyclic derivatives of 4-(tert-butyl)-3-methoxybenzoic acid as EGFR tyrosine kinase allosteric site inhibitors
by: Imad M. Al-Rubaye, et al.
Published: (2024-01-01)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
by: Tasia Amelia, et al.
Published: (2022-01-01)

Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis
by: Caiyan Jia, et al.
Published: (2024-01-01)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with <i>EGFR</i> Mutations
by: Kenichi Suda, et al.
Published: (2021-06-01)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
by: Xingyuan Li, et al.
Published: (2023-10-01)

Novel 7-Deazapurine Incorporating Isatin Hybrid Compounds as Protein Kinase Inhibitors: Design, Synthesis, In Silico Studies, and Antiproliferative Evaluation
by: Mohammed M. Alanazi, et al.
Published: (2023-08-01)

Discovery of Natural Inhibitors of Cholinesterases from <i>Hydrangea</i>: In Vitro and In Silico Approaches
by: Jayeong Hwang, et al.
Published: (2021-01-01)

Discovery of New Inhibitors of eEF2K from Traditional Chinese Medicine Based on In Silico Screening and In Vitro Experimental Validation
by: Qinghua Fu, et al.
Published: (2022-07-01)

Novel Potential Janus Kinase Inhibitors with Therapeutic Prospects in Rheumatoid Arthritis Addressed by In Silico Studies
by: Andrei-Flavius Radu, et al.
Published: (2023-06-01)

Combination of Virtual Screening Protocol by in Silico toward the Discovery of Novel 4-Hydroxyphenylpyruvate Dioxygenase Inhibitors
by: Ying Fu, et al.
Published: (2018-02-01)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
by: Keigo Kobayashi
Published: (2023-12-01)

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
by: Daniel B Costa, et al.
Published: (2007-10-01)

Discovery of new symmetrical and asymmetrical nitrile-containing 1,4-dihydropyridine derivatives as dual kinases and P-glycoprotein inhibitors: synthesis, in vitro assays, and in silico studies
by: Mohamed H. Saad, et al.
Published: (2022-12-01)

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity
by: Takahiro Yoshizawa, et al.
Published: (2021-04-01)

Screening For Potential Inhibitors Of Mycobacterium Tuberculosis Isocitrate Lyase: In Silico And In Vitro Approaches
by: Lee , Yie Vern
Published: (2017)

In silico and in vitro screening of pyrrole-based Hydrazide-Hydrazones as novel acetylcholinesterase inhibitors
by: Emilio Mateev, et al.
Published: (2024-02-01)

TNBC Therapeutics Based on Combination of Fusarochromanone with EGFR Inhibitors
by: Natalie Carroll, et al.
Published: (2022-11-01)

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in <i>EGFR</i>-Mutated NSCLC
by: Keigo Kobayashi, et al.
Published: (2023-02-01)

In Vitro High Throughput Screening, What Next? Lessons from the Screening for Aurora Kinase Inhibitors
by: Thi-My-Nhung Hoang, et al.
Published: (2014-02-01)

Scaffold Repurposing of In-House Small Molecule Candidates Leads to Discovery of First-in-Class CDK-1/HER-2 Dual Inhibitors: In Vitro and In Silico Screening
by: Ahmed Elkamhawy, et al.
Published: (2021-09-01)

Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
by: Yu-ra Choi, et al.
Published: (2022-03-01)

ALGORITHMS FOR MANAGEMENT OF PATIENTS WITH ADVERSE EVENTS ON THERAPY WITH TYROSINE KINASE INHIBITORS EGFR
by: D. D. SAKAEVA
Published: (2017-06-01)

Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors.
by: Yun Jung Choi, et al.
Published: (2013-01-01)

Allosteric Kinase Inhibitors Reshape MEK1 Kinase Activity Conformations in Cells and In Silico
by: Jakob Fleischmann, et al.
Published: (2021-03-01)

Multi-Target In Silico Prediction of Inhibitors for Mitogen-Activated Protein Kinase-Interacting Kinases
by: Amit Kumar Halder, et al.
Published: (2021-11-01)

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors
by: Ikei S. Kobayashi, MD, PhD, et al.
Published: (2024-01-01)

Bioinformatics and drug discovery /
by: Larson, Richard S.
Published: (2005)

Discovery of novel acetylcholinesterase inhibitors through integration of machine learning with genetic algorithm based in silico screening approaches
by: Mohd Imran Khan, et al.
Published: (2023-03-01)

In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors
by: Teresa Żołek, et al.
Published: (2023-07-01)